Trial Profile

A Study to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KPI 012 (Primary)
Indications Corneal injuries
Focus Registrational; Therapeutic Use
Acronyms CHASE
Sponsors Combangio Inc; KALA BIO

Most Recent Events

22 Oct 2025 Status changed from active, no longer recruiting to discontinued, due to lack of efficacy.
29 Sep 2025 Primary endpoint (Response status) has not been met as per results published in the KALA BIO Media Release
29 Sep 2025 Results published in the KALA BIO Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com